Development of biodegradable nanocarriers loaded with a monoclonal antibody

Andrew Gdowski, Amalendu Ranjan, Anindita Mukerjee, Jamboor Vishwanatha

Research output: Contribution to journalArticle

19 Scopus citations


Treatments utilizing monoclonal antibody therapeutics against intracellular protein-protein interactions in cancer cells have been hampered by several factors, including poor intracellular uptake and rapid lysosomal degradation. Our current work examines the feasibility of encapsulating monoclonal antibodies within poly(lactic-co-glycolic acid) (PLGA) nanoparticles using a water/oil/water double emulsion solvent evaporation technique. This method can be used to prepare protective polymeric nanoparticles for transporting functional antibodies to the cytoplasmic compartment of cancer cells. Nanoparticles were formulated and then characterized using a number of physical and biological parameters. The average nanoparticle size ranged from 221 to 252 nm with a low polydispersity index. Encapsulation efficiency of 16%–22% and antibody loading of 0.3%–1.12% were observed. The antibody molecules were released from the nanoparticles in a sustained manner and upon release maintained functionality. Our studies achieved successful formulation of antibody loaded polymeric nanoparticles, thus indicating that a PLGA-based antibody nanoformulation is a promising intracellular delivery vehicle for a large number of new intracellular antibody targets in cancer cells.

Original languageEnglish
Pages (from-to)3990-3995
Number of pages6
JournalInternational journal of molecular sciences
Issue number2
StatePublished - 12 Feb 2015


  • Antibody
  • Cancer
  • Formulation
  • Nanoparticle
  • PLGA
  • Therapy

Fingerprint Dive into the research topics of 'Development of biodegradable nanocarriers loaded with a monoclonal antibody'. Together they form a unique fingerprint.

  • Cite this